Castle Biosciences CSTL Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's share-based payment award options outstanding - number?
- Castle Biosciences (CSTL) reported share-based payment award options outstanding - number of 2.7M in Q1 2026.
- How has Castle Biosciences's share-based payment award options outstanding - number changed year-over-year?
- Castle Biosciences's share-based payment award options outstanding - number decreased by 7.5% year-over-year, from 3M to 2.7M.
- What is the long-term trend for Castle Biosciences's share-based payment award options outstanding - number?
- Over 5 years (2020 to 2025), Castle Biosciences's share-based payment award options outstanding - number has grown at a -3.7% compound annual growth rate (CAGR), from 3.4M to 2.8M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.